Item 8.01 Other Events.

On December 3, 2008, Advanced Life Sciences announced that the U.S. Food and Drug Administration (FDA) accepted and filed the Company's New Drug Application (NDA) for cethromycin in the treatment of mild-to-moderate community acquired pneumonia. The FDA has established a goal of a standard 10-month review such that the anticipated target action date of the cethromycin NDA would be July 31, 2009.

A copy of the press release dated December 3, 2008 announcing filing of the NDA by the FDA is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

99.1 Press Release dated December 3, 2008.

---